Bio3 Research s.r.l. is a private biopharmaceutical company based in Milan, Italy, with a USA subsidiary,Bio3 Research Inc. based in Walnut Creek/CA.

Bio3 Research develops new proprietary compounds up to Phase I/Phase IIA stage in:

Development activity is ongoing in the area of cardiovascular disorders related to HMGB1 (High Mobility Group Box 1) over-expression.

Preclinical studies have shown that the HMGB1 protein as such and its fragments have potential in Connective Tissue Regeneration (wound healing, cartilage repair, bone matrix regeneration, burns, bedsores etc).

Nephrology is another Bio3 Research field of interest.

Bio3 Research collaborates with biopharmaceutical companies, Academies, individual scientists, to identify commercially promising innovations to patent and develop them for commercial fruition in the pharmaceutical marketplace.